Patents by Inventor Deborah Hurst
Deborah Hurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170081416Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: August 19, 2016Publication date: March 23, 2017Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman (deceased), Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20140205602Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: December 19, 2013Publication date: July 24, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Patent number: 8637032Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: September 12, 2012Date of Patent: January 28, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20130011405Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: September 12, 2012Publication date: January 10, 2013Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Patent number: 8277810Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: October 31, 2007Date of Patent: October 2, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20080254026Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: October 31, 2007Publication date: October 16, 2008Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Publication number: 20080057070Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing cells, such as B cells.Type: ApplicationFiled: November 4, 2004Publication date: March 6, 2008Applicant: Chiron CorporationInventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20070274948Abstract: Methods for treating a human with chronic lymphocytic leukemia using a combination of an interleukin-2 and an anti-CD52 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing an IL-2, the other containing an anti-CD2 antibody, according to a dosing regiment. Administering of these two therapeutic agents together results in a positive therapeutic response that is improved with respect to that observed with anti-CD52 antibody alone.Type: ApplicationFiled: June 4, 2004Publication date: November 29, 2007Inventors: Deborah Hurst, Cornelia Quadt, Maurice Wolin, Sandra Milan, Anders Osterborg
-
Patent number: 6694523Abstract: The specification and drawings describe and show one or more embodiments of the present invention in the form of a compression glove for selective application for treatment of hand, wrist, forearm and thumb discomfort. Useful for prevention and relief of injuries caused by repetitive motions while handling implements, it has a flexible waterproof glove body with exposed fingertips. The glove includes a pair or series of layers of hermetically sealed material, that can capture pressurized air, when applied therein. It is formed through the patterned sealing of the layers of the glove together at select locations. This forms inflatable chambers that can selectively apply isolated points of pressure and support to the affected area.Type: GrantFiled: May 21, 2002Date of Patent: February 24, 2004Inventor: Deborah Hurst
-
Publication number: 20030217404Abstract: The specification and drawings describe and show one or more embodiments of the present invention in the form of a compression glove for selective application for treatment of hand, wrist, forearm and thumb discomfort. Useful for prevention and relief of injuries caused by repetitive motions while handling implements, it has a flexible waterproof glove body with exposed fingertips. The glove includes a pair or series of layers of hermetically sealed material, that can capture pressurized air, when applied therein. It is formed through the patterned sealing of the layers of the glove together at select locations. This forms inflatable chambers that can selectively apply isolated points of pressure and support to the affected area.Type: ApplicationFiled: May 21, 2002Publication date: November 27, 2003Inventor: Deborah Hurst
-
Publication number: 20030185796Abstract: Methods for treating a human with lymphoma using a combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing IL-2, the other containing at least one anti-CD20 antibody, according to a dosing regimen. Administering of these two therapeutic agents together potentiates the effectiveness of either agent alone, resulting in a positive therapeutic response that is improved with respect to that observed with either agent alone. The therapeutic effects of these agents can be achieved using lower dosages of IL-2, thereby lessening the toxicity of prolonged IL-2 administration and the potential for tumor escape.Type: ApplicationFiled: November 12, 2002Publication date: October 2, 2003Applicant: Chiron CorporationInventors: Maurice J. Wolin, Sandra Milan, Deborah Hurst